Details of the Drug
General Information of Drug (ID: DM560Y3)
| Drug Name |
Morantel tartrate
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Paratect; Banminth II; MORANTEL TARTRATE SALT; Morantel tartrate [USAN]; Morantel tartrate hydrate; CP 12009-18; Morantel tartrate (USP); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-, tartrate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-,tartrate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-,(R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); (E)-1,4,5,6-Tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)pyrimidine tartrate (1:1); 1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine; 2,3-dihydroxybutanedioic acid
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Therapeutic Class |
Anthelmintics
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 |
Molecular Weight | 370.4 | |||||||||||||||||
| Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||
| Rotatable Bond Count | 5 | ||||||||||||||||||
| Hydrogen Bond Donor Count | 4 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count | 8 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||


